SCHEMBL10244752

SCHEMBL10244752

CCNC1CCN(C(C)c2ccccc2OC)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
DRD3 P35462 1/20 0.42
SIGMAR1 Q99720 1/20 0.40
BCHE P06276 3/20 0.40
ACHE P22303 3/20 0.40
BACE1 P56817 3/20 0.40
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
HTR1A P08908 2/20 0.39
HTR7 P34969 2/20 0.39
MCHR1 Q99705 1/20 0.39
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
MC4R P32245 1/20 0.38
EHMT2 Q96KQ7 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12608606 1.00 DRD2 (0.42) DRD2DRD4DRD3SIGMAR1BCHE
SCHEMBL10282645 0.85 MCHR1 (0.41) DRD2DRD4DRD3SIGMAR1MEN1
SCHEMBL12566127 0.82 MCHR1 (0.39) SIGMAR1MEN1POLBKMT2AHTR1A
SCHEMBL12566115 0.82 MCHR1 (0.39) SIGMAR1MEN1POLBKMT2AHTR1A
SCHEMBL10244724 0.78 MCHR1 (0.48) DRD2HTR1AHTR7MCHR1ALDH1A1
SCHEMBL1132838 0.77 CHRM2 (0.41) DRD2DRD3ACHEMEN1KMT2A
SCHEMBL1133387 0.77 CHRM2 (0.41) DRD2DRD3ACHEMEN1KMT2A
SCHEMBL334807 0.77 CHRM2 (0.41) DRD2DRD3ACHEMEN1KMT2A
SCHEMBL13553415 0.77 CHRM2 (0.44) MC4RCHRM2CHRM4CHRM5CHRM1
SCHEMBL11886647 0.74 CHRM2 (0.46) MC4RCHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 DRD2 1514/4885DRD4 910/4885DRD3 1207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.